Hypoglycemics
CA 2067738 A1 · Owner: Amylin Pharmaceuticals, Inc. · Inventors: Moore, Candace X.; Cooper, Garth J. S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Non-insulin dependent or type 2, diabetes mellitus is treated by administration of a hypoglycemic agent that enhances plasma concentrations of amylin and of an amylin antagonist. The hypoglycemic agent can be a sulfonurea or a biguanide. The amylin antagonist can be an amylin or a calcitonin gene-related peptide having altered reactive sites or being cross-linked or truncated. Patients are also monitored for enhanced plasma concentrations of amylin following administration of hypoglycemic agents and the effects, of agents on the secretion of amylin in biological system such as a cell culture of islet beta cells is monitored by an assay.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 14, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 14, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 14, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.